Download Sample
Add to CartType 2 Diabetes Market
By Drug Class;
Insulins, DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 InhibitorsBy Application;
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and OthersBy End User;
Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Introduction
Global Type 2 Diabetes Market (USD Million), 2021 - 2031
In the year 2024, the Global Type 2 Diabetes Market was valued at USD 36,575.41 million. The size of this market is expected to increase to USD 63,287.60 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.1%.
Type 2 Diabetes Market
*Market size in USD million
CAGR 8.1 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 8.1 % |
| Market Size (2024) | USD 36,575.41 Million |
| Market Size (2031) | USD 63,287.60 Million |
| Market Concentration | Medium |
| Report Pages | 312 |
Major Players
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Merck & Co., Inc.
- AstraZeneca
- Johnson & Johnson
- Boehringer Ingelheim
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Type 2 Diabetes Market
Fragmented - Highly competitive market without dominant players
The global Type 2 diabetes market encompasses a wide array of pharmaceuticals, medical devices, diagnostics, and digital health solutions aimed at managing and treating Type 2 diabetes, a chronic metabolic disorder characterized by insulin resistance and high blood sugar levels. With an escalating prevalence worldwide, driven by sedentary lifestyles, unhealthy dietary habits, and aging populations, Type 2 diabetes poses a significant public health challenge, exerting immense economic and healthcare burdens on individuals, communities, and healthcare systems.
Market players in the global Type 2 diabetes market operate in a dynamic landscape shaped by evolving patient needs, technological innovations, regulatory frameworks, and market competition. Key market drivers such as innovation in treatment modalities, rising disease prevalence, and technological advancements in diabetes management drive market growth and spur investments in research and development, product commercialization, and market expansion strategies.
However, the market also faces notable challenges, including high treatment costs, limited access to healthcare services, regulatory hurdles, and persisting stigma surrounding diabetes. Addressing these challenges necessitates collaborative efforts from healthcare stakeholders, policymakers, industry players, and patient advocacy groups to foster innovation, improve healthcare infrastructure, enhance disease awareness, and promote equitable access to diabetes care worldwide.
Global Type 2 Diabetes Market Recent Developments
-
In May 2022, Eli Lilly and Company announced that the U.S. FDA has approved Mounjaro (tirzepatide) injection, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1 =) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Mounjaro, the first and only S. FDA-approved GIP and GLP-1 receptor agonist, is a single molecule that activates the body's receptors for GIP and GLP-1, both natural incretin hormones.
-
In April 2023, Eli Lilly and Company, a pharmaceutical company, announced that tirzepatide (10 mg and 15 mg) resulted in more weight loss than placebo after 72 weeks of treatment in SURMOUNT-2. The study found that tirzepatide outperformed placebo in terms of both co-primary and key secondary objectives. The trial included 938 adult volunteers with obesity or overweight and type 2 diabetes.
Type 2 Diabetes Market Segment Analysis
In this report, the Type 2 Diabetes Market has been segmented by Drug Class, Application, End User and Geography.
Type 2 Diabetes Market, Segmentation by Drug Class
The Type 2 Diabetes Market has been segmented by Drug Class into, Insulins, DPP-4 Inhibitors, GLP-1 Receptor Agonists and SGLT-2 Inhibitors.
Insulins
Insulins account for around 40–42% of the Type 2 Diabetes market, remaining the primary treatment for patients with advanced disease or inadequate glycemic control on oral therapies. This segment grows at 3–4% annually, driven by rising adoption of long-acting and ultra-rapid formulations.
DPP-4 Inhibitors
DPP-4 inhibitors hold about 20–22% share, valued for their oral administration, low hypoglycemia risk, and broad patient tolerability. The segment grows at 2–3% annually, supported by combination therapy use with other glucose-lowering agents.
GLP-1 Receptor Agonists
GLP-1 receptor agonists represent approximately 18–20% of the market, showing the highest growth at 7–8% annually due to their weight loss benefits, cardiovascular protection, and strong clinical outcomes in glucose control.
SGLT-2 Inhibitors
SGLT-2 inhibitors account for about 15–17% share, growing at 6–7% annually. Their uptake is supported by proven renal benefits, cardiovascular risk reduction, and use in combination therapies for better glycemic management.
Type 2 Diabetes Market, Segmentation by Application
The Type 2 Diabetes Market exhibits diverse has been segmented by application into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others.
Hospital Pharmacies
Hospital pharmacies account for around 40–42% of the Type 2 Diabetes market, primarily serving inpatients and post-discharge prescriptions. This segment grows at 3–4% annually, supported by the availability of specialist consultations and advanced treatment options.
Retail Pharmacies
Retail pharmacies hold about 35–37% share, benefiting from widespread accessibility and established distribution networks. The segment grows at 4–5% annually, driven by repeat prescriptions and patient preference for face-to-face pharmacist interactions.
Online Pharmacies
Online pharmacies represent approximately 15–17% of the market, expanding rapidly at 8–9% annually due to digital convenience, home delivery services, and the rise in telemedicine-based prescriptions.
Others
Other distribution channels make up 6–8% of the market, including clinics, healthcare centers, and government supply programs. Growth at 2–3% annually is supported by community-based healthcare initiatives.
Type 2 Diabetes Market, Segmentation by End User
The Type 2 Diabetes Market exhibits diverse has been segmented by End User into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes and Others
Homecare Settings
Homecare settings account for around 30–32% of the Type 2 Diabetes market, supported by the growing use of self-monitoring devices and insulin delivery systems. This segment grows at 6–7% annually, driven by patient preference for convenience and remote healthcare support.
Hospitals & Clinics
Hospitals and clinics hold approximately 40–42% share, serving as primary treatment and diagnosis centers for diabetes patients. Growth at 3–4% annually is supported by specialized care, advanced diagnostic facilities, and management of complex cases.
Academic & Research Institutes
Academic and research institutes represent about 15–17% of the market, focusing on clinical trials, drug development, and technology innovation in diabetes care. The segment grows at 4–5% annually, fueled by research funding and collaboration with pharmaceutical companies.
Others
Other end users, including community health programs and government healthcare initiatives, account for 8–10% of the market. Growth at 2–3% annually is driven by outreach programs aimed at early detection and prevention.
Type 2 Diabetes Market, Segmentation by Geography
In this report, the Type 2 Diabetes Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
Type 2 Diabetes Market Share (%), by Geographical Region
North America
North America accounts for around 35–38% of the Type 2 Diabetes market, driven by high disease prevalence, advanced healthcare infrastructure, and access to innovative therapies. The region grows at 4–5% annually, supported by strong adoption of digital diabetes management tools.
Europe
Europe holds approximately 28–30% share, with demand fueled by government-funded healthcare programs and early diagnosis initiatives. The market expands at 3–4% annually, supported by increased use of GLP-1 receptor agonists and other advanced treatment classes.
Asia Pacific
Asia Pacific represents 25–28% of global demand, showing the fastest growth at 7–8% annually. Rising urbanization, lifestyle-related risk factors, and healthcare infrastructure investments are key growth drivers in this region.
Middle East & Africa
Middle East & Africa account for about 5–6% share, growing at 4–5% annually due to increasing awareness, improved access to diagnostic services, and government-led health campaigns targeting diabetes prevention and management.
Latin America
Latin America contributes 5–6% of the market, with growth at 3–4% annually. Expanding healthcare coverage, rising obesity rates, and greater availability of modern diabetes drugs are fueling demand.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Type 2 Diabetes Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Innovation in Treatment
- Rising Prevalence Rates
- Technological Advancements
- Lifestyle Changes
-
Aging Population Growth : The global population aging at an unprecedented rate, the prevalence of Type 2 diabetes is expected to surge. This demographic shift is primarily attributed to improved healthcare and lifestyle changes leading to increased life expectancy. As individuals age, their susceptibility to chronic conditions like Type 2 diabetes rises, driving the demand for diabetes management and treatment options.
Aging populations also present a unique set of challenges, including comorbidities and complexities in managing diabetes alongside other age-related health issues. Healthcare providers and policymakers must devise comprehensive strategies to address the unique needs of elderly diabetes patients, focusing on personalized care plans, geriatric-friendly interventions, and caregiver support systems.
Moreover, the aging population represents a substantial market for innovative solutions targeting age-related diabetes complications and geriatric-specific treatment modalities. From specialized medications to assistive technologies tailored for older adults, there exists a significant opportunity for healthcare stakeholders to cater to this demographic segment's evolving needs.
Restraints
- High Treatment Costs
- Limited Access
- Regulatory Hurdles
- Stigma and Awareness
-
Healthcare Infrastructure : Despite advancements in diabetes management, disparities in healthcare infrastructure persist, especially in underserved regions and developing countries. Inadequate healthcare facilities, shortage of skilled medical professionals, and limited access to essential medications hinder effective diabetes management and exacerbate the burden of the disease on affected populations.
The lack of comprehensive healthcare infrastructure not only impedes timely diagnosis and treatment but also contributes to the escalation of diabetes-related complications and economic burdens on healthcare systems. Addressing these infrastructure gaps requires concerted efforts from governments, international organizations, and private sector stakeholders to invest in healthcare infrastructure development, capacity building, and sustainable healthcare delivery models.
Furthermore, disparities in healthcare infrastructure perpetuate health inequities, disproportionately affecting marginalized communities, including rural populations and socioeconomically disadvantaged individuals. Bridging the gap in healthcare access and infrastructure requires a multifaceted approach encompassing policy reforms, investment in primary healthcare services, and leveraging innovative technologies to enhance healthcare delivery efficiency and reach.
Opportunities
- Personalized Medicine Approach
- Emerging Markets Expansion
- Digital Health Solutions
- Prevention Initiatives
-
Collaborative Research Efforts : Collaborative research efforts play a pivotal role in advancing our understanding of Type 2 diabetes etiology, treatment modalities, and prevention strategies. By fostering interdisciplinary collaborations among researchers, healthcare professionals, and industry stakeholders, innovative solutions can be developed to address unmet needs in diabetes management, ranging from novel therapeutics to precision medicine approaches tailored to individual patient profiles.
The synergistic exchange of knowledge, resources, and expertise in collaborative research initiatives facilitates the translation of scientific discoveries into clinical applications, accelerating the pace of innovation in diabetes care. Moreover, collaborative research networks provide a platform for data sharing, enabling large-scale studies and real-world evidence generation essential for informing clinical practice guidelines and health policy decisions.
Beyond scientific advancement, collaborative research efforts also foster partnerships between academia, industry, and patient advocacy groups, driving patient-centered research agendas and ensuring that diabetes research priorities align with patient needs and preferences. By engaging diverse stakeholders in the research process, collaborative initiatives promote inclusivity, transparency, and accountability, ultimately enhancing the relevance and impact of diabetes research outcomes.
Competitive Landscape Analysis
Key players in Global Type 2 Diabetes Market include :
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Merck & Co., Inc.
- AstraZeneca
- Johnson & Johnson
- Boehringer Ingelheim
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Type 2 Diabetes Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Innovation in Treatment
- Rising Prevalence Rates
- Technological Advancements
- Lifestyle Changes
- Aging Population Growth
- Restraints
- High Treatment Costs
- Limited Access
- Regulatory Hurdles
- Stigma and Awareness
- Healthcare Infrastructure
- Opportunities
- Personalized Medicine Approach
- Emerging Markets Expansion
- Digital Health Solutions
- Prevention Initiatives
- Collaborative Research Efforts
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Type 2 Diabetes Market, By Drug Class, 2021 - 2031 (USD Million)
- Insulins
- DPP-4 inhibitors
- GLP-1 receptor agonists
- SGLT-2 inhibitors
- Type 2 Diabetes Market, By Application, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
-
Type 2 Diabetes Market, By End User, 2021 - 2031 (USD Million)
-
Homecare Settings
-
Hospitals & Clinics
-
Academic & Research Institutes
-
Others
-
- Type 2 Diabetes Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Type 2 Diabetes Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Merck & Co., Inc.
- AstraZeneca
- Johnson & Johnson
- Boehringer Ingelheim
- Company Profiles
- Analyst Views
- Future Outlook of the Market